[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10202003100XA - Bacteria Engineered to Reduce Hyperphenylalaninemia - Google Patents

Bacteria Engineered to Reduce Hyperphenylalaninemia

Info

Publication number
SG10202003100XA
SG10202003100XA SG10202003100XA SG10202003100XA SG10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA
Authority
SG
Singapore
Prior art keywords
bacteria engineered
hyperphenylalaninemia
reduce
reduce hyperphenylalaninemia
engineered
Prior art date
Application number
SG10202003100XA
Inventor
Dean Falb
Vincent Isabella
Jonathan Kotula
Paul Miller
Sarah Rowe
Yves Millet
Original Assignee
Synlogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic Operating Co Inc filed Critical Synlogic Operating Co Inc
Publication of SG10202003100XA publication Critical patent/SG10202003100XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
SG10202003100XA 2015-05-13 2016-05-13 Bacteria Engineered to Reduce Hyperphenylalaninemia SG10202003100XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562161137P 2015-05-13 2015-05-13
US201562256052P 2015-11-16 2015-11-16

Publications (1)

Publication Number Publication Date
SG10202003100XA true SG10202003100XA (en) 2020-05-28

Family

ID=56117975

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202003100XA SG10202003100XA (en) 2015-05-13 2016-05-13 Bacteria Engineered to Reduce Hyperphenylalaninemia

Country Status (12)

Country Link
US (6) US9889164B2 (en)
EP (2) EP3882259A1 (en)
JP (3) JP6843768B2 (en)
AU (2) AU2016262569B9 (en)
BR (1) BR112017024384A2 (en)
CA (1) CA2985819A1 (en)
ES (1) ES2881384T3 (en)
IL (2) IL296538A (en)
PL (1) PL3294760T3 (en)
SG (1) SG10202003100XA (en)
WO (1) WO2016183531A1 (en)
ZA (1) ZA201707678B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020136119A (en) 2014-04-01 2021-05-17 Рубиус Терапьютикс, Инк. METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2016183532A1 (en) * 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
EP3563684A1 (en) 2015-05-06 2019-11-06 Snipr Technologies Limited Altering microbial populations & modifying microbiota
AU2016262569B9 (en) 2015-05-13 2021-09-16 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
AU2016356684C1 (en) * 2015-11-16 2022-11-10 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
CA3048669A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
WO2018191715A2 (en) * 2017-04-14 2018-10-18 Synthetic Genomics, Inc. Polypeptides with type v crispr activity and uses thereof
US11879123B2 (en) 2017-06-21 2024-01-23 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
AU2017430856B2 (en) 2017-09-08 2024-07-04 New Portal Limited Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
CN107904222B (en) * 2017-11-30 2019-10-08 江南大学 A kind of l-amino acid deaminase mutant and its construction method that thermal stability improves
CN111918960A (en) * 2017-12-05 2020-11-10 比奥普来克斯有限公司 Methods and compositions for preventing microbial infections
WO2020132017A1 (en) * 2018-12-20 2020-06-25 University Of South Carolina Pharmabiotic treatments for metabolic disorders
JP2022530503A (en) 2019-04-29 2022-06-29 シンロジック オペレーティング カンパニー インコーポレイテッド Genetically engineered microorganisms
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
WO2020257707A1 (en) * 2019-06-21 2020-12-24 Ginkgo Bioworks, Inc. Biosynthesis of enzymes for use in treatment of maple syrup urine disease (msud)
CN110257291B (en) * 2019-06-25 2021-07-23 北京大学 Achromobacter capable of tolerating nickel ion toxicity and application thereof
WO2021059240A1 (en) 2019-09-27 2021-04-01 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
IL292836A (en) 2019-11-12 2022-07-01 Actym Therapeutics Inc Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
CN115003790A (en) 2020-01-17 2022-09-02 鲁汶大学 Genetically modified bacteria with altered envelope integrity and uses thereof
WO2021173808A1 (en) * 2020-02-25 2021-09-02 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
CN115298308A (en) 2020-03-20 2022-11-04 同生运营公司 Microorganisms engineered to reduce hyperphenylalaninemia
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
EP4176053A2 (en) * 2020-07-02 2023-05-10 The Regents of the University of California Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
CA3191433A1 (en) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
IL302604A (en) * 2020-11-10 2023-07-01 Palena Therapeutics Inc Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use
WO2022120028A2 (en) 2020-12-02 2022-06-09 Synlogic Operating Company, Inc. Engineered microorganisms
CN112501098B (en) * 2020-12-11 2023-01-03 上海陶宇晟生物技术有限责任公司 Engineering probiotics with phenylalanine degrading capability
US20240316121A1 (en) 2020-12-31 2024-09-26 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
CN112662606A (en) * 2021-01-06 2021-04-16 中国科学院分子植物科学卓越创新中心 Engineering probiotics for treating phenylketonuria
CN112662607A (en) * 2021-01-07 2021-04-16 上海陶宇晟生物技术有限责任公司 Engineering probiotics with surface display of phenylalanine ammonia lyase
EP4340819A1 (en) * 2021-06-24 2024-03-27 Lonza Greenwood LLC Method to control administration of active substance to the digestive tract
CA3235418A1 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN116836899A (en) * 2022-03-02 2023-10-03 和度生物技术(上海)有限公司 Engineering microorganism for treating hyperphenylalaninemia and application thereof
CN114717172B (en) * 2022-03-21 2022-09-23 江南大学 Escherichia coli for synthesizing L-valine and construction method and application thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116463362B (en) * 2023-06-15 2023-09-19 中国中医科学院中药研究所 Preparation method of cell division inhibitor

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (en) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 Genetic engineering fungus oral prepration capable of expressing active phenylalanine deaminase
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
AU3108400A (en) 1998-12-02 2000-06-19 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (en) 2003-09-08 2010-04-21 味の素株式会社 Novel transporter protein
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (en) * 2008-05-22 2012-03-07 北京三元基因工程有限公司 Method for preparing product of active lactic acid galactococcus
DK3181682T3 (en) 2008-09-29 2021-07-05 Intrexon Actobiotics Nv REDUCED COLONIZATION OF MICROBES ON THE MUCKINS
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US9017961B2 (en) 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
ES2709217T3 (en) * 2012-06-22 2019-04-15 Phytogene Inc Enzymes and methods for the synthesis of styrene
US20150246083A1 (en) 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
WO2014066945A1 (en) * 2012-11-01 2014-05-08 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-modified probiotic for treatment of phenylketonuria
US9951340B2 (en) 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
SG11201704543XA (en) * 2014-12-05 2017-07-28 Synlogic Inc Bacteria engineered to treat diseases associated with hyperammonemia
WO2016183532A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
AU2016262569B9 (en) 2015-05-13 2021-09-16 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
CA2988981A1 (en) * 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism

Also Published As

Publication number Publication date
IL255616B (en) 2022-10-01
IL296538A (en) 2022-11-01
AU2016262569B2 (en) 2021-05-06
CA2985819A1 (en) 2016-11-17
US20180280451A9 (en) 2018-10-04
US10933102B2 (en) 2021-03-02
US20160340665A1 (en) 2016-11-24
JP7245271B2 (en) 2023-03-23
US9889164B2 (en) 2018-02-13
JP2021097685A (en) 2021-07-01
JP6843768B2 (en) 2021-03-17
WO2016183531A1 (en) 2016-11-17
ES2881384T3 (en) 2021-11-29
US20200246394A1 (en) 2020-08-06
EP3882259A1 (en) 2021-09-22
BR112017024384A2 (en) 2018-07-24
IL255616B2 (en) 2023-02-01
US20170312320A1 (en) 2017-11-02
US20180169154A1 (en) 2018-06-21
JP2018515106A (en) 2018-06-14
US10610546B2 (en) 2020-04-07
JP2023085295A (en) 2023-06-20
US10195234B2 (en) 2019-02-05
AU2016262569B9 (en) 2021-09-16
PL3294760T3 (en) 2021-11-08
AU2021212141B2 (en) 2024-09-19
AU2021212141A1 (en) 2021-08-26
ZA201707678B (en) 2021-03-31
US20170014457A1 (en) 2017-01-19
US20170136073A1 (en) 2017-05-18
EP3294760B1 (en) 2021-03-24
IL255616A (en) 2018-01-31
AU2016262569A1 (en) 2018-01-04
EP3294760A1 (en) 2018-03-21
US9943555B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
ZA201707678B (en) Bacteria engineered to reduce hyperphenylalaninemia
IL278150A (en) Bacteria engineered to treat diseases associated with hyperammonemia
HK1257676A1 (en) Engineered crispr-cas9 nucleases
HK1252666A1 (en) Antibodies to cd40
PL3377518T3 (en) Bacteria engineered to reduce hyperphenylalaninemia
GB201514489D0 (en) Hyperphenylalaninemia
GB2541833B (en) Improvements to implant surfaces
HK1252613A1 (en) 6-amino-quinoline-3-carbonitrils as cot modulators
GB201409541D0 (en) Probiotic Bacteria
GB201408039D0 (en) Culture dish
GB201515330D0 (en) Bioreactor condenser
GB201519450D0 (en) Novel treatment
GB201514420D0 (en) Bioreactor
GB2538045B (en) Improvements to letter-plates
GB201514734D0 (en) Mechanical bioreactor
HK1253094A1 (en) Multi-peptide composition
GB201520827D0 (en) Bioreactor
GB2522473B (en) Improvements to windposts
GB201517420D0 (en) Improvements to bedpans
GB201518810D0 (en) Bioreactor
GB201517290D0 (en) Bioreactor
GB201521028D0 (en) Improvements to Li-fi
GB2520781B (en) Improvements to hydro-turbines
GB201501181D0 (en) Ready-to-assemble pond
PL3137475T3 (en) Purification of epidaunorubicin